Sunday 15 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
What it owns vs. what it owes End of fiscal 2025, 31 December 2025
Liabilities are $65.9M more than assets: shareholders’ equity is negative. What is a balance sheet?
Owns
$70.0KLong-term assets
$119.0KOther short-term assets
$89.2MCash & short-term investments
Funded by
$155.2MOther liabilities
Debt is 0.0% of the total; liabilities are $65.9M more than assets.
| Dec '25 | |
|---|---|
Cash and Short Term Investments |
89.16 |
Total current assets |
89.28 |
Long-term assets (Other) |
0.07 |
Total non-current assets |
0.07 |
Total Assets |
89.35 |
Accounts Payable |
1.06 |
Accrued Expenses |
4.18 |
Total current liabilities |
5.24 |
Preferred Shares of Subsidiary (Mandatory, Redeemable) |
149.89 |
Non-current Liabilities (Other) |
0.09 |
Total non-current liabilities |
149.98 |
Total liabilities |
155.22 |
Additional Paid In Capital |
0.18 |
Common Stock (Net) |
0.00 |
Retained Earnings |
(66.05) |
Common Equity (Total) |
(65.87) |
Shareholders Equity (Total) |
(65.87) |
Shareholders Equity and Liabilities (Total) |
89.35 |
Shares (Common) |
6.69 |
Shareholders Equity (Tangible) |
(65.87) |
Net Debt |
(89.16) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026